Sorrento Therapeutics, Inc. And IGDRASOL Announce Presentation On Non-Biologic Nanoparticle Paclitaxel (NBN-Pac) Formulations For The Treatment Of Solid Tumors At The Nanomedicine 2013 Meeting In Barcelona, Spain
"We intend to leverage our comprehensive domain knowledge of paclitaxel nanoparticle formulations to build a franchise of next generation paclitaxel nanomedicines. I am convinced that our team who played a key role in the development and success of Abraxane® will be able to do it here again," said Vuong Trieu Ph.D., Chief Executive Officer of IGDRASOL.
Also, the acquisition of TOCOSOL® paclitaxel allows IGDRASOL to compare and contrast stable paclitaxel nanoparticles (TOCOSOL® paclitaxel) versus plasma-unstable paclitaxel nanoparticles (Abraxane® and Genexol-PM®). Data mining of these large databases have generated exciting insights into the field of nanomedicine.
Some of the findings are being presented at Nanomedicine 2013, April 11 th -12 th, Barcelona, Spain. The presentation is entitled: "Non-biologic Nanoparticle Paclitaxel for the Treatment of Cancer" authored by: Vuong Trieu, Catherine Cheng, Larn Hwang, Chao Hsiao, and Kouros Motamed.
About Cynviloq™Cynviloq™ (or IG-001; a paclitaxel-loaded micellar diblock copolymer) is a next-generation branded paclitaxel formulation currently approved and on the market in several countries as Genexol-PM®. About Sorrento Therapeutics, Inc. Sorrento Therapeutics, Inc. ("STI"; SRNE) is a publicly-traded, development-stage biopharmaceutical company focused on the discovery, development and commercialization of novel and proprietary biotherapeutics for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic and infectious diseases. STI's objective is to identify drug development candidates derived from its proprietary human antibody libraries and, either independently or through partnerships, advance selected targets into preclinical or clinical development. In 2012, STI identified and further developed a number of potential drug product candidates across various therapeutic areas, and STI intends to select several lead product candidates to progress into preclinical development activities in 2013. More information is available at www.sorrentotherapeutics.com. About IGDRASOL IGDRASOL's lead therapeutic platform is Cynviloq™, a branded micellar paclitaxel formulation which is free of cremophor and human serum albumin (HSA), the excipients for Taxol® (cremophor-based paclitaxel) and albumin-bound paclitaxel (Abraxane®), respectively. Cynviloq™ combines the simplicity of manufacturing and preparation of Taxol® and potentially the albumin-mediated transport of paclitaxel. IGDRASOL intends to conduct registration trials for multiple cancer indications.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV